GILLIS EDWARD M 4

What Happened

• Edward M. Gillis, Senior Vice President, Devices at BioCardia, had 17,269 shares withheld by the company on July 2, 2026 to satisfy income tax withholding related to RSUs that vested June 29, 2026 (reported disposition value $21,414 at $1.24/share). Per the filing footnote, this withholding was performed by the issuer and does not represent a sale by the reporting person.
• On July 6, 2026 the filing also reports a grant/acquisition of 29,442 derivative shares (reported at $0). A footnote clarifies the award is tied to an option that vests 1/48th of the shares beginning August 6, 2026 and monthly thereafter, subject to continued service.

Key Details

• Transaction dates/prices: July 2, 2026 — 17,269 shares withheld at $1.24 ($21,414); July 6, 2026 — 29,442-share derivative grant, $0 reported.
• Shares owned after transaction: Not specified in the filing.
• Footnotes: F1 = shares withheld by issuer for taxes (not a sale by the insider). F2 = option vests 1/48th monthly starting Aug 6, 2026 (4-year monthly vesting schedule).
• Filing timeliness: Form 4 filed July 7, 2026 for transactions on July 2 and July 6 — appears timely (within standard reporting window).

Context

• The July 2 withholding is a routine tax withholding following RSU vesting (not an open-market sale) and generally does not signal a change in insider sentiment.
• The July 6 entry is a derivative award/option with multi-year monthly vesting; such awards are common compensation and only become meaningful over the vesting period.
• No indication in this filing that the insider is a 10% owner or that a 10b5-1 plan was used.